23,226 results on '"CHRONIC myeloid leukemia"'
Search Results
2. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
3. A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML (POLARIS-2)
4. Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
5. PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML (PEARL)
6. Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
7. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
8. Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France (ASSURE-3)
9. The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
10. Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
11. Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
12. De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE)
13. CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
14. Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
15. Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial (MAST)
16. HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (OPTIMIZE)
17. A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia (CML)
18. A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
19. Special Drug Use-results Surveillance of Scemblix Tablets
20. HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
21. Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
22. Asciminib RMP Study
23. Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (ENESTop)
24. Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
25. Off-the-shelf NK Cells + SCT for Myeloid Malignancies
26. Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. (KIWIS)
27. Occupational Status and Hematological Disease (EMATO0113)
28. The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia (TIRE)
29. Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
30. Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion (HAPLOTAB)
31. A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
32. International Chronic Myeloid Leukemia Pediatric Study (ICMLPed)
33. Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia (PHARM-LMC)
34. Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (AVENHIR)
35. Imatinib dose reduction after major molecular response in chronic‐phase chronic myeloid leukemia.
36. Hsa_circ_0006010 and hsa_circ_0002903 in peripheral blood serve as novel diagnostic, surveillance and prognostic biomarkers for disease progression in chronic myeloid leukemia.
37. Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia.
38. Multi‐response kinetic study of Maillard reaction hazards in the glucose‐lysine model system.
39. 慢性髓性白血病伴附加染色体异常疗效及预后的相关性分析.
40. Choice of Frontline Tyrosine‐Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A “Campus CML” Study.
41. Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia.
42. Late presentation of chronic myeloid leukaemia patients in a low-income country: the prognostic implications and impact on treatment outcome.
43. Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data.
44. A novel time‐varying coefficient Poisson difference model driven by observation.
45. Biphenylsulfonamides as effective MMP‐2 inhibitors with promising antileukemic efficacy: Synthesis, in vitro biological evaluation, molecular docking, and MD simulation analysis.
46. circ_0080145 Enhances Imatinib Resistance of Chronic Myeloid Leukemia by Regulating miR-326/PPFIA1 Axis.
47. Proteomic Dynamics of Multidrug Resistance Mechanisms in Lucena 1 Cell Line.
48. Minimal Requirements for Cancer Initiation: A Comparative Consideration of Three Prototypes of Human Leukemia.
49. Investigation and assessment of oxidant – antioxidant status of some enzymes and vitamins in Iraqi patients with chronic myeloid leukemia.
50. Bone marrow findings post allogeneic transplant for myeloproliferative neoplasms and chronic myelomonocytic leukemia with increased fibrosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.